Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001240673 | SCV001413642 | uncertain significance | Cerebral creatine deficiency syndrome | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces tryptophan with leucine at codon 174 of the GAMT protein (p.Trp174Leu). The tryptophan residue is highly conserved and there is a small physicochemical difference between tryptophan and leucine. This variant is present in population databases (rs200444143, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with GAMT-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782681 | SCV005394401 | uncertain significance | not specified | 2024-09-15 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001828958 | SCV002087017 | uncertain significance | Deficiency of guanidinoacetate methyltransferase | 2020-01-10 | no assertion criteria provided | clinical testing |